SCHEMBL7337191

SCHEMBL7337191

CCOC(=O)CCCOc1ccc(C2=NNC(=O)CC2)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
NPY1R P25929 1/20 0.50
NPY2R P49146 1/20 0.50
PDE4B Q07343 3/20 0.49
PDE3B Q13370 3/20 0.49
PDE3A Q14432 3/20 0.49
PDE4A P27815 2/20 0.49
PDE4C Q08493 2/20 0.49
PDE4D Q08499 2/20 0.49
MAPT P10636 4/20 0.47
HPGD P15428 5/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 3/20 0.43
TSHR P16473 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
BRD4 O60885 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4573518 0.89 PDE3B (0.52) LMNANPY1RNPY2RPDE4BPDE3B
SCHEMBL7327893 0.87 PDE3B (0.52) LMNANPY1RNPY2RPDE4BPDE3B
SCHEMBL4888905 0.84 PDE3B (0.52) LMNANPY1RNPY2RPDE4BPDE3B
SCHEMBL7336619 0.84 LMNA (0.72) LMNANPY1RNPY2RPDE4BPDE3B
SCHEMBL8191155 0.83 PDE3B (0.61) LMNANPY1RNPY2RPDE4BPDE3B
SCHEMBL4890576 0.82 PDE3B (0.54) LMNANPY1RNPY2RPDE4BPDE3B
SCHEMBL4903296 0.80 PDE3B (0.54) LMNANPY1RNPY2RPDE4BPDE3B
SCHEMBL7337183 0.80 PDE3B (0.49) LMNANPY1RNPY2RPDE4BPDE3B
SCHEMBL8266841 0.79 PDE3B (0.53) LMNANPY1RNPY2RPDE4BPDE3B
SCHEMBL7333826 0.79 TP53 (0.47) LMNANPY1RNPY2RPDE4BPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5204463-A Substituted methoxyphenyl-4,5 dihydro-3(2H)-pridazinones having cardiotonic and beta blocking activities GLAXO INC. (US) 1993-04-20 US disclosed
US-5096904-A Congestive heart failure GLAXO INC. (US) 1992-03-17 US disclosed
US-5053338-A Hydrolysis of ester to obtain an optically enriched mixture of a phenol enantiomer GLAXO INC. (US) 1991-10-01 US disclosed
EP-0412814-A2 Pyridazinones having cardiotonic and beta blocking activity GLAXO WELLCOME INC. (US) 1991-02-13 EP disclosed